

Joint Commission *of* Pharmacy Practitioners

November, 2022

ORGANIZATION: American Association of Psychiatric Pharmacists (AAPP)-Formerly known as the College of Psychiatric and Neurologic Pharmacists (CPNP)

- Action Plan Implementation Activity

- Pharmacists' Patient Care Process
- Value of Pharmacists' Patient Care Services
 - Published 4 additional practice profiles illustrating the impact of psychiatric pharmacists on patient care in transitions of care, correctional health care, pediatric psychiatry, and caring for the older adult.
 - Completed initial work on systematic review of the impact of psychiatric pharmacists on patient care.
 - Developing a core set of patient outcomes impacted by psychiatric pharmacists to help standardize clinical research and to inform potential payment models.
 - Developing an employer resource center that will work on justifications and on curating integration strategies.
 - Three publicly available toolkits have been released in the past 6 months providing clinical guidance on buprenorphine dosing, management of agitation and aggression, and cannabis use disorder: <https://aapp.org/ed/suds>
 - Relevant Mental Health Clinician Journal Articles:
 - Pharmacist impact on medication reconciliation of behavioral health patients boarding in the emergency department
<https://meridian.allenpress.com/mhc/article/12/3/187/482848/Pharmacist-impact-on-medication-reconciliation-of>
 - Addition of a clinical pharmacist practitioner to an inpatient addiction triage team and related medication outcomes:
<https://meridian.allenpress.com/mhc/article/12/4/219/485318/Addition-of-a-clinical-pharmacist-practitioner-to>
- Provider Status Recognition
 - Multiple meetings of the AAPP interprofessional advisory council to consider key practice issues from the standpoint of other professions.
 - AAPP has been active in distributing comment letters on MH and SUD funding, legislation, and regulation, scope of practice, and telehealth regulation and legislation: <https://cpnp.org/govt/letters-statements>
 - AAPP participated in a SAMHSA invite only meeting on August 11-12, 2022: SAMHSA Policy Priority Meeting on Buprenorphine Access and Availability in Pharmacy Settings. This presented an opportunity to advocate for pharmacist inclusion in the care team and payment for services.
 - Interviewed by Clinical Trial Network (CTN) of the National Institute on Drug Abuse (NIDA) on a research project titled: Assessment and Design of a Collaborative MOUD Delivery System. The project is designed to engage experts in addiction treatment, pharmacy operations, and process engineering to explore opportunities for improving access to medications for opioid use disorder (MOUDs) through pharmacies. The project examines the business case and community impact for pharmacies to reduce barriers to obtaining and sustaining MOUDs.

Organization Update (other information):

- AAPP Board elections have been completed and the following individuals elected.
 - **Jolene Bostwick, PharmD, BCPS, BCPP, Member-at-Large**, Assistant Dean for Co-Curriculum and Professional Development & Clinical Professor, University of Michigan College of Pharmacy, Ann Arbor, MI
 - **Michelle Geier, PharmD, BCPP, Incoming President-Elect**, Psychiatric Clinical Pharmacist Supervisor, San Francisco Department of Public Health, San Francisco, CA
 - **Kristina Reinstatler, PharmD, MBA, BCPP, Member-at-Large**, Clinical Pharmacy Specialist, UC Health University of Cincinnati Medical Center, Cincinnati, OH
- AAPP will be providing administrative support to one set of mentor-mentee awardees from The National Institute of Drug Abuse (NIDA) – Clinical Trials Network (CTN) Mentor-Facilitated Training (MFT) award. This program supports advancement of expertise in substance use disorder (SUD) through a mentored experience. The project to be completed is focused on Improving Buprenorphine Treatment Access in Community Pharmacies Through Best Practices Dissemination
- Transition to the new name of American Association of Psychiatric Pharmacists (AAPP) has largely occurred with all final steps to conclude by end of 2022.
- Monitoring and input to the FDA modernization of the REMS program continues given its impact on Clozapine patients.
- Planning for the April 16-19, AAPP 2023 Annual Meeting is well underway. Posters are accepted through January 11, 2023 at <https://aapp.org/ed/meeting/2023/abstract>
- The second virtual Summit on Substance Use Disorders was offered for BCPP and ACPE credit with nearly 300 registrants to date: <https://aapp.org/ed/summit/2022>. The Summit is intended to focus on emerging areas of practice and in 2023 will be themed to The Integration of Mental Health into Primary Care. Aligned with this area of policy emphasis, AAPP will also be commenting on an AHRQ [RFI](#) asking for data and evidence regarding the integration of behavioral health into primary care.